pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
daraxonrasib · news · pharmadog
← back to daraxonrasib
News mentioning daraxonrasib
50
stories
Jun 4, 26
What RevMed’s pancreatic cancer drug meant for one patient
stat
Jun 4, 26
STAT+: For pancreatic cancer patients, an exciting drug can feel out of reach
stat
Jun 4, 26
STAT+: Does Revolution Medicines’ pancreatic cancer drug have even greater potential?
stat
Jun 1, 26
STAT+: At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways
stat
Jun 1, 26
STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more
stat
Jun 1, 26
STAT+: A turning point for pancreatic cancer patients
stat
May 31, 26
STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug
stat
May 31, 26
‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancer
biopharma dive
May 30, 26
STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug
stat
May 14, 26
ASCO 2026: All Eyes Are on Daraxonrasib and a Wave of Novel Targeted Therapies in GI Malignancies
onclive
May 10, 26
Five Under 5: Top Oncology Videos for the Week of 5/3
onclive
May 9, 26
The OncFive: Top Oncology Articles for the Week of 5/3
onclive
May 8, 26
Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhD
onclive
May 7, 26
Daraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic Cancer
onclive
May 7, 26
STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more
stat
May 6, 26
Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinoma
onclive
May 6, 26
Dr Pant on the Mechanism of Action of Daraxonrasib in PDAC
onclive
May 5, 26
Dr Pant on Managing Toxicities With Daraxonrasib in PDAC
onclive
Apr 27, 26
STAT+: Erasca touts strong, though preliminary, results in trial of pancreatic and lung cancer therapy
stat
Apr 22, 26
Revolution drug shows promise in early pancreatic cancer
biopharma dive
← prev
page 2 of 2
next →
